Years when CDTi is expected to be stopped in endemic African regions.

<p>Years when CDTi is expected to be stopped in endemic African regions.</p

Cumulative number of ivermectin treatments and annual number of projects with ongoing CDTi in endemic African regions, 2013–2045.

<p>Cumulative number of ivermectin treatments and annual number of projects with ongoing CDTi in endemic African regions, 2013–2045.</p

Total population living in ongoing and potential new project areas in endemic African countries (numbers, % of total population in endemic regions), 2014.

<p>Total population living in ongoing and potential new project areas in endemic African countries (numbers, % of total population in endemic regions), 2014.</p

One-way deterministic sensitivity analysis for the cumulative number of ivermectin treatments over 2013–2045.

<p>One-way deterministic sensitivity analysis for the cumulative number of ivermectin treatments over 2013–2045.</p

Proposed scenarios of control, elimination, and eradication of onchocerciasis.

<p>¹ Political insecurity and co-endemicity with <i>Loa loa</i>.</p><p>² Hypo-endemic areas with feasibility concerns were included in the eradication scenario only.</p><p>³ Twice a year in new projects in Ethiopia and Uganda where the respective ministries of health announced six-monthly CDTi in new projects to bring them in line with ongoing projects [<a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0003664#pntd.0003664.ref020" target="_blank">20</a>,<a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0003664#pntd.0003664.ref021" target="_blank">21</a>]</p><p>⁴ Predicted considering APOC’s strategic plan to focus on the onchocerciasis elimination for the next decade 2016–2025 and the current epidemiological and political situation</p><p>⁵ A dynamical transmission model ONCHOSIM [<a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0003664#pntd.0003664.ref022" target="_blank">22</a>] was used.</p><p>Proposed scenarios of control, elimination, and eradication of onchocerciasis.</p

One-way deterministic sensitivity analysis for the years when CDTi is expected to be stopped in endemic African regions.

<p>CONTROL also applies to the countries with feasibility concerns in the elimination scenario. ELIMINATION excludes countries with feasibility concerns.</p

Population in target areas and the cumulative number of required ivermectin treatments in endemic African regions.

<p>Population in target areas and the cumulative number of required ivermectin treatments in endemic African regions.</p

Endemic countries in Africa.

<p>* countries with epidemiological or political insecurity issues</p><p>** non-endemic with possible exception of small border areas with Malawi and Tanzania</p><p>Endemic countries in Africa.</p

Costs per round for annual and semiannual mass drug administration, by activity and cost item.

<p>Costs per year and per treatment round for annual and semiannual mass drug administration programs, per 100,000 eligible persons, in 2009 US$. Cost for West Africa were based on detailed data from Burkina Faso. See <a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0001984#pntd-0001984-t002" target="_blank">Table 2</a> for data sources and calculation steps.</p><p>Abbrevations: DEC = diethylcarbamazine, ALB = albendazole, IVM = ivermectin.</p>a<p>including administration for West Africa.</p>b<p>including training of personnel for India.</p>c<p>including supervision and enumeration for West Africa.</p>d<p>It is assumed that drugs were purchased for all persons eligible for MDA.</p

Sensitivity analysis: impact of cost assumptions on the relative cost of semiannual/annual mass drug administration (MDA).

<p>The values in the table are the ratio of total program costs, for semiannual MDA/annual MDA. This ratio shows which approach is less expensive (with values <1 indicating that semiannual MDA is less expensive and vice versa), and it provides an indication of the relative differences in cost. Between brackets, the total program costs estimates are given for semiannual/annual MDA programs, in 2009 US$ ×1000. <a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0001984#s3" target="_blank">Results</a> are shown for Indian and West African settings, with varying pre-control mf prevalence levels. Coverage of MDA was assumed to be 70% per round (percentage of total population). The number of treatment rounds required for elimination differs between these settings (see <a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0001984#pntd-0001984-t004" target="_blank">table 4</a>) and hence the total program costs. Given levels of mf prevalence are based on diagnosis with 60 µL blood smears.</p><p>n.r.: not relevant, because costs of drugs, which are all donated, are not included in the cost projections.</p>a<p>baseline assumptions.</p